AzurRx (AZRX) Corporate Media Kit

8 PERT MS1819 Drug Substance Porcine-derived pancreatic enzyme replacement therapy (PERT) Recombinant yeast ( Yarrowia lipolytica ) lipase-derived replacement therapy Stability in Acidic GI Environment Limited More stable Safety Adverse event: fibrosing colonopathy at high doses Safe and well tolerated and no risk of fibrosing colonopathy Pill Burden 25-40 pills per day (CF) 8-16 pills per day (CF) Sourcing & Supply • Subject to pig herd management • Risk of transmission of animal pathogens • Manufacturing + supply chain inconsistency • GRAS (Generally Regarded as Safe) • No risk of animal pathogens • Manufacturing + supply chain consistency Sources: Results from the Company’s clinical trials, internal studies and management estimates. MS1819: Fulfilling an Unmet Medical Need